Kura Oncology to Participate in Credit Suisse Healthcare Conference

Rhea-AI Summary

Kura Oncology, Inc. (Nasdaq: KURA) announced its participation in the Credit Suisse 30th Annual Healthcare Conference. The event features a virtual fireside chat with CEO Troy Wilson on November 9, 2021, at 3:30 p.m. ET. Investors can access a live audio webcast on Kura's website, with a replay available afterward. Kura specializes in precision medicines for cancer, focusing on small molecule drug candidates. Key programs include KO-539 for relapsed/refractory AML and Tipifarnib for HRAS mutant head and neck cancer, highlighting the company's innovative approach to oncology.

SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Credit Suisse 30^th Annual Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 3:30 p.m. ET / 12:30 p.m. PT on Tuesday, November 9, 2021.

A live audio webcast of the fireside chat will be available in the Investors section of Kura’s website at www.kuraoncology.com, with a replay available shortly after the live event.

About Kura Oncology

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates that target cancer signaling pathways. KO-539, a potent and selective menin inhibitor, is currently in a Phase 1b clinical trial (KOMET-001) for patients with relapsed/refractory AML, including patients with NPM1 mutations or KMT2A rearrangements. Tipifarnib, a potent, selective and orally bioavailable farnesyl transferase inhibitor, has received Breakthrough Therapy Designation for the treatment of patients with HRAS mutant HNSCC and is currently in a registration-directed study (AIM-HN) in patients with this devastating disease. In addition, Kura is pursuing the use of tipifarnib in combination with other oncology therapeutics to address larger genetic subsets of patients, including those who have HRAS- and/or PIK3CA-dependent HNSCC. The Company is also developing KO-2806, a next-generation farnesyl transferase inhibitor, which is intended to target innovative biology and larger oncology indications through rational combinations. For additional information about Kura, please visit the Company’s website at www.kuraoncology.com.

Contacts

Company:
Pete De Spain
Vice President, Investor Relations &
Corporate Communications
(858) 500-8803
pete@kuraoncology.com

Investors:
Robert H. Uhl
Managing Director
Westwicke ICR
(858) 356-5932
robert.uhl@westwicke.com

Media:
Jason Spark
Managing Director
Canale Communications
(619) 849-6005
jason@canalecomm.com

FAQ

When is Kura Oncology's virtual fireside chat scheduled?

Kura Oncology's virtual fireside chat is scheduled for November 9, 2021, at 3:30 p.m. ET.

How can I access the Kura Oncology fireside chat?

You can access the Kura Oncology fireside chat via a live audio webcast on the company's website.

What is Kura Oncology's focus in cancer treatment?

Kura Oncology focuses on precision medicines for cancer, developing small molecule drug candidates targeting cancer signaling pathways.

What is the status of Kura Oncology's KO-539 drug?

KO-539 is currently in a Phase 1b clinical trial for patients with relapsed/refractory AML.

What breakthrough designation has Kura Oncology received?

Kura Oncology's Tipifarnib has received Breakthrough Therapy Designation for treating patients with HRAS mutant head and neck squamous cell carcinoma.